PUBLISHER: Acute Market Reports | PRODUCT CODE: 1180692
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1180692
Neurological Diseases Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
The neurological diseases treatment market is observed as the most diversified and competitive market comprising large number of players globally. The key driving factors assisting the growth of these two segments are rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to presence of strong drug pipeline is expected to impact the market share of traditional drug treatments and further boost the overall growth of this market. Rising research and development activities in the field of neurology has been the key driver for neurological diseases treatment market and is expected to fuel its growth throughout the forecast period (2022 - 2030). The neurological diseases treatment market is expected to grow at a CAGR of 5.1% during the forecast period 2022-2030.
Anticholinergic and Antiepileptic Segment Led the Market revenues in 2021
The anticholinergic and antiepileptic segment alone contribute to over 44% of the revenue share in 2021. This is largely due to increased focus on R&D in these drugs segment and its application in controlling muscle movement. Increasing prevalence of neurological disorders remains as the key driver to market growth.
Treatment for Alzheimer's Top the Market Revenues
Based on therapeutic segment, Alzheimer's disease dominated the market segment in 2021. Intense R&D initiatives are the key reason for the largest share of Alzheimer's segment, apart from other drivers such as increasing prevalence rate across the globe. Alzheimer's is also expected to retain its top positon throughout the forecast period. Parkinson's disease remains as the second largest market for neurological treatment drugs market.
APAC to Grow the Fastest
After scrutiny of the neurological diseases treatment market, regional trends, market sizes, and the overall growth paired with the latest and anticipated events, Asia Pacific is observed to be the most attractive region for the neurological diseases treatment market owing to a swift growth in the uptake of medicines to prevent surging disabilities, death and to improvise on quality of living.
Drug Approvals and Pipelines Remain the Key Focus Area Among the Top Players
It is evident that drug related activities are the most preferred strategy among the top players. Drug related activities include drug approval across various geographies, presenting clinical trial outcomes, receiving permission to launch neurology drugs in various phases of clinical trials. Strategies such as mergers and acquisitions and partnerships & collaborations are comparatively insignificant in this market. Other strategies include receiving recognitions, creating awareness, participation in neurology related events and so on. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis, GSK, Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neurological Diseases Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Neurological Diseases Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drugs
Anticholinergic
Antiepileptic
Antipsychotic
Hypnotic & Sedative
Analgesics
Antihypertensive
Anticoagulants
Others
Therapeutic
Epilepsy
Alzheimer's disease
Parkinson's disease
Multiple Sclerosis
Cerebrovascular disease
Others
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Neurological Diseases Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Neurological Diseases Treatment market?
Which is the largest regional market for Neurological Diseases Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Neurological Diseases Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Neurological Diseases Treatment market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Neurological Diseases Treatment Market
- 2.2. Global Neurological Diseases Treatment Market, By Drugs, 2021 (US$ Million)
- 2.3. Global Neurological Diseases Treatment Market, By Therapeutic, 2021 (US$ Million)
- 2.4. Global Neurological Diseases Treatment Market, By Geography, 2021 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2021
3. Neurological Diseases Treatment Market: Competitive Analysis
- 3.1. Market Positioning of Key Neurological Diseases Treatment Market Vendors
- 3.2. Strategies Adopted by Neurological Diseases Treatment Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Neurological Diseases Treatment Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Neurological Diseases Treatment Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Anticholinergic
- 5.3.2. Antiepileptic
- 5.3.3. Antipsychotic
- 5.3.4. Hypnotic & Sedative
- 5.3.5. Analgesics
- 5.3.6. Antihypertensive
- 5.3.7. Anticoagulants
- 5.3.8. Others
6. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Epilepsy
- 6.3.2. Alzheimer's disease
- 6.3.3. Parkinson's disease
- 6.3.4. Multiple Sclerosis
- 6.3.5. Cerebrovascular disease
- 6.3.6. Others
7. North America Neurological Diseases Treatment Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 7.3. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 7.4.Neurological Diseases Treatment Market: By Region, 2020-2030, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 7.4.1.1.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 7.4.1.2.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 7.4.1.3.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Neurological Diseases Treatment Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.3. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.Neurological Diseases Treatment Market: By Region, 2020-2030, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.1.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.2.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.3.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.4.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.5.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 8.4.1.6.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Neurological Diseases Treatment Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.3. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.Neurological Diseases Treatment Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.1.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.2.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.3.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.4.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.5.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 9.4.1.6.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Neurological Diseases Treatment Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 10.3. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 10.4.Neurological Diseases Treatment Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 10.4.1.1.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 10.4.1.2.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 10.4.1.3.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Neurological Diseases Treatment Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 11.3. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 11.4.Neurological Diseases Treatment Market: By Region, 2020-2030, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 11.4.1.1.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 11.4.1.2.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2020-2030, USD (Million)
- 11.4.1.3.1. Neurological Diseases Treatment Market: By Therapeutic, 2020-2030, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. Novartis AG.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. GlaxoSmithKline plc.
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. Merck & Co.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. Bayer AG.
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. AstraZeneca plc.
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. Boehringer Ingelheim GmbH.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. Teva Pharmaceutical Industries Ltd.
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. F. Hoffmann-La Roche AG.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
- 12.9. Zogenix, Inc.
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
- 12.10. Eisai Co., Ltd.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Initiatives
- 12.11. AZTherapies, Inc.
- 12.11.1. Company Overview
- 12.11.2. Financial Performance
- 12.11.3. Product Portfolio
- 12.11.4. Strategic Initiatives
- 12.12. Biogen, Inc.
- 12.12.1. Company Overview
- 12.12.2. Financial Performance
- 12.12.3. Product Portfolio
- 12.12.4. Strategic Initiatives
- 12.13. Intra-Cellular Therapies, Inc.
- 12.13.1. Company Overview
- 12.13.2. Financial Performance
- 12.13.3. Product Portfolio
- 12.13.4. Strategic Initiatives
- 12.14. Avid Radiopharmaceuticals.
- 12.14.1. Company Overview
- 12.14.2. Financial Performance
- 12.14.3. Product Portfolio
- 12.14.4. Strategic Initiatives
- 12.15. Avanir Pharmaceuticals.
- 12.15.1. Company Overview
- 12.15.2. Financial Performance
- 12.15.3. Product Portfolio
- 12.15.4. Strategic Initiatives
- 12.16. Johnson & Johnson (Janssen Pharmaceuticals).
- 12.16.1. Company Overview
- 12.16.2. Financial Performance
- 12.16.3. Product Portfolio
- 12.16.4. Strategic Initiatives
- 12.17. Sunovion Pharmaceuticals Inc.
- 12.17.1. Company Overview
- 12.17.2. Financial Performance
- 12.17.3. Product Portfolio
- 12.17.4. Strategic Initiatives
- 12.18. AbbVie, Inc.
- 12.18.1. Company Overview
- 12.18.2. Financial Performance
- 12.18.3. Product Portfolio
- 12.18.4. Strategic Initiatives
- 12.19. NeuroDerm Ltd.
- 12.19.1. Company Overview
- 12.19.2. Financial Performance
- 12.19.3. Product Portfolio
- 12.19.4. Strategic Initiatives
- 12.20. MedDay Pharmaceuticals SA.
- 12.20.1. Company Overview
- 12.20.2. Financial Performance
- 12.20.3. Product Portfolio
- 12.20.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 2 Global Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 3 North America Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 4 North America Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 5 U.S. Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 6 U.S. Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 7 Canada Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 8 Canada Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 9 Rest of North America Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 10 Rest of North America Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 11 UK and European Union Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 12 UK and European Union Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 13 UK Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 14 UK Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 15 Germany Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 16 Germany Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 17 Spain Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 18 Spain Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 19 Italy Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 20 Italy Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 21 France Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 22 France Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 23 Rest of Europe Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 24 Rest of Europe Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 25 Asia Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 26 Asia Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 27 China Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 28 China Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 29 Japan Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 30 Japan Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 31 India Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 32 India Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 33 Australia Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 34 Australia Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 35 South Korea Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 36 South Korea Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 37 Latin America Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 38 Latin America Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 39 Brazil Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 40 Brazil Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 41 Mexico Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 42 Mexico Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 43 Rest of Latin America Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 44 Rest of Latin America Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 45 Middle East and Africa Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 46 Middle East and Africa Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 47 GCC Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 48 GCC Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 49 Africa Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 50 Africa Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
- TABLE 51 Rest of Middle East and Africa Neurological Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
- TABLE 52 Rest of Middle East and Africa Neurological Diseases Treatment Market By Therapeutic, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Neurological Diseases Treatment Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Neurological Diseases Treatment Market: Quality Assurance
- FIG. 5 Global Neurological Diseases Treatment Market, By Drugs, 2021
- FIG. 6 Global Neurological Diseases Treatment Market, By Therapeutic, 2021
- FIG. 7 Global Neurological Diseases Treatment Market, By Geography, 2021
- FIG. 8 Market Geographical Opportunity Matrix - Global Neurological Diseases Treatment Market, 2021
- FIG. 9 Market Positioning of Key Neurological Diseases Treatment Market Players, 2021
- FIG. 10 Global Neurological Diseases Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
- FIG. 11 Global Neurological Diseases Treatment Market, By Drugs, 2021 Vs 2030, %
- FIG. 12 Global Neurological Diseases Treatment Market, By Therapeutic, 2021 Vs 2030, %
- FIG. 13 U.S. Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 14 Canada Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 15 Rest of North America Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 16 UK Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 17 Germany Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 18 Spain Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 19 Italy Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 20 France Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 21 Rest of Europe Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 22 China Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 23 Japan Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 24 India Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 25 Australia Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 26 South Korea Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 27 Rest of Asia Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 28 Brazil Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 29 Mexico Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 30 Rest of Latin America Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 31 GCC Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 32 Africa Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
- FIG. 33 Rest of Middle East and Africa Neurological Diseases Treatment Market (US$ Million), 2020 - 2030
